Ischemic Heart Disease Articles & Analysis
10 news found
The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...
This prospective, multicenter registry will enroll up to 400 female patients with symptomatic ischemic heart disease in up to 50 investigational centers in the United States and Europe and will include a 3-year follow-up. ...
With its ready-to-use models and assays for cardiac diseases, customers can accurately analyze the relationship between diseases and mitochondria. Mitochondrial DNA (mtDNA) plays an important role in the pathogenesis of the cardiovascular disease (CVD), especially in heart failure and ischemic ...
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this year XyloCor ...
He most recently co-founded Reprieve Cardiovascular and led the company’s financing and development of a highly unique therapy for acute decompensated heart failure (ADHF). Mr. Dillon's career focus in heart failure has included developing therapies to enable native heart recovery, reduce the size of a patient’s myocardial infarction, ...
Hanover, Germany, February 9, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two ...
“We are very pleased that the InEK continues to support patient access to our innovative LIVE Therapy, which published studies have shown improves heart function, patient symptoms, activity level and quality of life for patients with scarred hearts after a heart attack,” said BioVentrix CEO Ken Miller LIVE™ Therapy uses the ...
“COVID-19 has been reported to cause or worsen heart damage, and with the progressive nature of heart failure, delays in treatment can worsen the prognosis for patients. ...
The company offers Less Invasive Ventricular Enhancement, or the LIVE™ Therapy, which uses the Revivent TC™ Transcatheter Ventricular Enhancement System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently. ...
A strong link between long-term exposure to vehicle pollution and deaths from heart disease and lung cancer has been found in a study of over a million individuals. ...